PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Zerenex (ferric citrate) long-term Phase 3 study results published in JASN

Data demonstrate the drug candidate's potential to become the first phosphate binder to increase iron stores while reducing the need for IV iron and erythropoiesis-stimulating agents in end-stage renal disease patients on dialysis

2014-07-25
(Press-News.org) New York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The PERFECTED study (PhosphatE binding and iRon delivery with FErric CiTrate in EsrD) was published online today in the Journal of the American Society of Nephrology (JASN).

This Phase 3 study was a multicenter, randomized, open-label trial in 441 ESRD patients on hemodialysis or peritoneal dialysis designed to determine the safety and efficacy of Zerenex as a treatment to reduce serum phosphorus as well as raise iron stores and reduce intravenous (IV) iron and erythropoietin-stimulating agents (ESA) usage.

Zerenex met the study's primary end-point demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Placebo Control Period. Using a sequential gatekeeping strategy for the key pre-defined secondary end-points, Zerenex also demonstrated statistically significant increases in serum ferritin and transferrin saturation (TSAT), and significant reductions in the use of IV iron and ESAs, versus an active control of Renvela® (sevelamer carbonate) and/or Phoslo® (calcium acetate) over the 52-week Active Control Period of the study. In addition, mean hemoglobin levels were higher in subjects treated with Zerenex as compared to subjects treated with active control.

"Zerenex effectively reduces serum phosphorus levels within the KDOQI range (3.5 mg/dL to 5.5 mg/dL) while having the additional patient benefits of increasing iron stores and decreasing the need for IV iron and ESAs, while maintaining hemoglobin levels," said Julia Lewis, MD, lead investigator, nephrologist and Professor of Medicine at Vanderbilt University Medical Center. "If approved, the combined benefits of Zerenex would be of value for patients, health care professionals and the healthcare system."

The Company's New Drug Application (NDA) for Zerenex is currently under review by the U.S. Food and Drug Administration (FDA).

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are very pleased with the publication of the Phase 3 PERFECTED study results in a premier peer-reviewed nephrology journal and are encouraged by Zerenex's potential differentiated product profile." Mr. Bentsur added, "We thank the investigators and patients who participated in this study and look forward to potentially bringing Zerenex to market in the U.S."

Phosphorus Control is Necessary for Most ESRD Patients on Dialysis

In the United States, according to data from the U.S. Renal Data System, there are currently approximately 600,000 ESRD patients, with the number of ESRD patients projected to rise in the future. The majority of ESRD patients in the United States, more than 400,000, require dialysis. Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are associated with secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and an increase in adverse cardiovascular events. Hyperphosphatemia is ubiquitous in ESRD, with the majority of the patients requiring chronic treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels.

Zerenex Administration Over 52 Weeks Increased Iron Stores

In addition, approximately seventy percent of dialysis patients are truly or functionally iron depleted, suffer from anemia and require treatment with IV iron and/or ESA injections. The newly published clinical trial results show that, in addition to its efficacy as a phosphate binder, Zerenex also significantly raises iron stores as measured by serum ferritin and TSAT.

The results showed Zerenex demonstrated a statistically significant treatment difference versus the active control group in mean change in serum ferritin (+306 ng/mL vs. +19 ng/mL) and TSAT (+8% vs -1.2%) from baseline (day 0) to week 52. In the PERFECTED study, subjects randomized to receive Zerenex required significantly lower dosages of IV iron and ESA; and hemoglobin levels were higher in Zerenex treated patients than in those receiving active control.

The investigators cited an analysis of the trial results that indicated that the projected reduction in the need for IV iron and ESA use would result in significant pharmaco-economic benefits. In addition, the investigators wrote, "one would postulate that decreased IV iron and ESA usage could result in decreased nursing time to administer IV medications which could be redirected to other aspects of patient care and decreased risk of infections due to fewer IV injections." In the PERFECTED study, fewer serious adverse events (SAEs) due to infection were seen in the subjects randomized to Zerenex compared to active control.

The authors noted that, if approved, Zerenex would be the only phosphate binder that also increases iron stores and decreases IV iron and ESA use.

Study Design and Results

Subjects in the PERFECTED study (n=441) first entered a 2-week washout period and were then randomized in a 2:1 ratio to receive either Zerenex or an active control of Renvela® (sevelamer carbonate) and/or Phoslo® (calcium acetate) for a 52-week Active Control Period. This was then followed by a 4-week Placebo Control Period in which Zerenex subjects were again randomized to either continue on Zerenex or switch to placebo. Zerenex was administered as 1 gram tablets each containing 210 mg of ferric iron. Active control study drugs were administered as calcium acetate 667 mg capsules, sevelamer carbonate 800 mg tablets alone or in combination.

The primary end-point of this trial was the mean change in serum phosphorus from baseline (Week 52) to the end of the 4-week Placebo Control Period. A prospectively designed sequential gatekeeping strategy controlled study-wise type 1 error for serum ferritin, TSAT, IV iron and ESA usage as pre-specified secondary endpoints in the 52-week Active Control Period.

The primary end-point demonstrated mean serum phosphorus was lower in the ferric citrate group versus the placebo group with a mean treatment difference of -2.2 ± 0.2 mg/dL (P END


ELSE PRESS RELEASES FROM THIS DATE:

New hope for powdery mildew resistant barley

New hope for powdery mildew resistant barley
2014-07-25
New research at the University of Adelaide has opened the way for the development of new lines of barley with resistance to powdery mildew. In Australia, annual barley production is second only to wheat with 7-8 million tonnes a year. Powdery mildew is one of the most important diseases of barley. Senior Research Scientist Dr Alan Little and team have discovered the composition of special growths on the cell walls of barley plants that block the penetration of the fungus into the leaf. The research, by the ARC Centre of Excellence in Plant Cell Walls in the University's ...

NRG1 isoforms could be an effective therapeutic candidate to promote peripheral nerve regeneration

2014-07-25
Neuregulin 1 (NRG1) is a pleiotropic factor characterized by the existence of numerous isoforms arising from alternative splicing of exons that confer to the protein deeply different characteristics. NRG1 plays an important role for both the myelination occurring during development and the different phases occurring after injury in the peripheral nerve: axon degeneration, axon regrowth, remyelination and target reinnervation Researchers at the University of Western Australia have discovered that the soluble NRG1 upregulation observed in Schwann cells immediately after ...

Assessment on self-care ability of children with spina bifda

2014-07-25
Spina bifda (SB) is a complex congenital central nervous system disease that is caused by the incomplete closing of the neural tubes during the embryonic phase. Many patients have varying degrees of spasticity, urinary and fecal incontinence and neurocognitive retardation. Such problems decrease the patients' functional independence and their quality of life. Researchers at Ankara Physical Medicine and Rehabilitation Education and Research Hospital, Turkey investigate the functional performance in children with SB, using the Pediatric Evaluation of Disability Inventory ...

Neurologic recovery from corticospinal tract injury due to subfalcine herniation

2014-07-25
After development of diffusion tensor tractography (DTT), which is derived from diffusion tensor imaging (DTI), three-dimensional reconstruction and estimation for three motor tracts, such as the corticospinal tract, the rubrospinal tract, and the corticoreticular pathway became possible. The corticospinal tract is known to be a major neural tract for motor function in the human brain. Several studies have reported on injury of the corticospinal tract by transtentorial herniation. In addition, some studies have demonstrated recovery of a corticospinal tract injured by transtentorial ...

Bacteria manipulate salt to build shelters to hibernate

Bacteria manipulate salt to build shelters to hibernate
2014-07-25
For the first time, Spanish researchers have detected an unknown interaction between microorganisms and salt. When Escherichia coli cells are introduced into a droplet of salt water and is left to dry, bacteria manipulate the sodium chloride crystallisation to create biomineralogical biosaline 3D morphologically complex formations, where they hibernate. Afterwards, simply by rehydrating the material, bacteria are revived. The discovery was made by chance with a home microscope, but it made the cover of the Astrobiology journal and may help to find signs of life on other ...

Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster

Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster
2014-07-25
A new study by researchers from the University of Leicester has furthered our understanding of how tiny nanosystems function, unlocking the potential to create new materials using nanosized 'building blocks'. The study, which has been published in the prestigious academic journal Physical Review Letters, used a novel laser technique to examine in rich detail the structure and internal atomic motion of a small cluster containing an acetylene molecule and a single helium atom. The technique excited single clusters and generated rotational wavepackets, which are composed ...

Magnets for fusion energy: A revolutionary manufacturing method developed

Magnets for fusion energy: A revolutionary manufacturing method developed
2014-07-25
The National Institute for Fusion Science (NIFS), of the National Institutes of Natural Sciences (NINS) in Japan, has achieved an electrical current of 100,000 amperes, which is by far the highest in the world, by using the new idea of assembling the state-of-the-art yttrium-based high-temperature superconducting tapes to fabricate a large-scale magnet conductor. NIFS is undertaking the development of a high-temperature superconducting coil that is appropriate for the fusion reactor magnet. Using the state-of-the-art yttrium-based high-temperature superconducting tapes ...

Physicists create tool to foresee language destruction impact and thus prevent it

2014-07-25
There have been numerous cases of cultural changes throughout history. Either by imposition or assimilation, cultural traits are transmitted between neighbouring regions and often one replaces the original cultural traits of the other. Physicists Joaquim Fort, from the University of Girona (UdG), and Neus Isern, from the Universitat Autònoma de Barcelona (UAB), are experts in modelling these phenomena by adequately representing a reality, as they have demonstrated with their previous projects. In this occasion, the researchers applied their expertise to the area of language ...

Collecting just the right data

2014-07-25
Much artificial-intelligence research addresses the problem of making predictions based on large data sets. An obvious example is the recommendation engines at retail sites like Amazon and Netflix. But some types of data are harder to collect than online click histories —information about geological formations thousands of feet underground, for instance. And in other applications — such as trying to predict the path of a storm — there may just not be enough time to crunch all the available data. Dan Levine, an MIT graduate student in aeronautics and astronautics, and ...

Could age of first period influence development of diseases in older women?

2014-07-25
BOSTON—A novel study shows that the age girls reach puberty is influenced by 'imprinted genes'—a subset of genes whose activity differs depending on which parent contributes the gene. This is the first evidence that imprinted genes can control the rate of development after birth and details of this study were published today in the journal Nature. Age of the first period, known as menarche, is a marker for the timing of puberty in females. Medical evidence shows that the onset of menses varies between girls, is an inherited trait, and is linked to breast cancer, diabetes ...

LAST 30 PRESS RELEASES:

New research boosts future whooping cough vaccines

Mechanistic understanding could enable better fast-charging batteries

No bones about it: new details about skeletal cell aging revealed

UNM scientists discover how nanoparticles of toxic metal used in MRI scans infiltrate human tissue

UMaine research examines best methods for growing Atlantic sea scallops

Medical cannabis could speed recovery, especially at community recovery homes

Study assesses U.S. image amid weakening of democracy

Two scientific researchers to receive 2025 Ralph L. Sacco Scholarships for Brain Health

Researchers improve chemical reaction that underpins products from foods to fuels

Texas Tech to develop semiconductor power devices through $6 million grant

Novel genomic screening tool enables precision reverse-engineering of genetic programming in cells

Hot Schrödinger cat states created

How cells repair their power plants

Oxygen is running low in inland waters—and humans are to blame

ACP’s Best Practice Advice addresses use of cannabis, cannabinoids for chronic noncancer pain

Beyond photorespiration: A systematic approach to unlocking enhanced plant productivity

How a small number of mutations can fuel outbreaks of western equine encephalitis virus

Exposure to wildfire smoke linked with worsening mental health conditions

Research uncovers hidden spread of one of the most common hospital-associated infections

Many older adults send their doctors portal messages, but who pays?

Fine particulate matter from 2020 California wildfires and mental health–related emergency department visits

Gender inequity in institutional leadership roles in US academic medical centers

Pancreatic cells ‘remember’ epigenetic precancerous marks without genetic sequence mutations

Rare combination of ovarian tumors found in one patient

AI-driven clinical recommendations may aid physician decision making to improve quality of care

Artificial intelligence has potential to aid physician decisions during virtual urgent care

ACP and Annals of Internal Medicine present breaking scientific news at ACP’s Internal Medicine Meeting 2025

New study reveals polymers with flawed fillers boost heat transfer in plastics

Signs identified that precede sudden arrhythmic death syndrome in young people

Discovery of bacteria's defence against viruses becomes a piece of the puzzle against resistance

[Press-News.org] Zerenex (ferric citrate) long-term Phase 3 study results published in JASN
Data demonstrate the drug candidate's potential to become the first phosphate binder to increase iron stores while reducing the need for IV iron and erythropoiesis-stimulating agents in end-stage renal disease patients on dialysis